Skip to main content

Table 2 The clinicopathological factors affecting CRC recurrence of all liver resections for hepatic metastasis

From: Prognostic significance of the number of tumors and aggressive surgical approach in colorectal cancer hepatic metastasis

Factors

Univariate analysis

Multivariate analysis

n

Medium RFS (m)

HR, (95% CI)

P- value

HR, (95% CI)

P- alue

Age (years)

      

 <55

108

12.9

1.16, (0.86 to 1.55)

0.327

—

—

 ≥55

224

14.7

1

   

Gender

      

 Male

225

15.1

1

0.608

—

—

 Female

107

11.2

1.08, (0.80 to 1.45)

   

Primary tumor

      

 Colon

206

15.1

1

0.232

—

—

 Rectum

126

12.0

1.11, (0.89 to 1.57)

   

Serum CEA (ng/mL)

      

 <100

294

15.1

1

<0.0001

1

0.001

 ≥100

38

6.3

3.15, (1.83 to 5.44)

 

2.06, (1.36 to 3.11)

 

Metastatic type

      

 Synchronous

153

14.8

1

0.757

1

0.744

 Metachronous

179

13.1

0.95, (0.72 to 1.26)

 

1.05, (0.79 to 1.40)

 

Number of tumors

      

 <4 nodules

285

15.4

1

0.001

1

0.041

 ≥4 nodules

47

8.3

2.22, (1.40 to 3.51)

 

1.53, (1.02 to 2.29)

 

Maximum tumor size (cm)

      

 <5

267

13.6

1.39, (0.99 to 1.95)

0.058

1.40, (0.95 to 2.06)

0.088

 ≥5

65

21.7

1

 

1

 

Distribution of metastasis

      

 Unilobar

239

15.9

1

0.025

1

0.399

 Bilobar

93

9.7

1.43, (1.40 to 1.98)

 

1.16, (0.82 to 1.63)

 

Extent of liver resection

      

 <3 segments

262

14.6

1

0.751

—

—

 ≥3 segments

70

13.1

0.95, (0.68 to 1.32)

   

Resection margin (mm)

      

 <0.5

142

11.5

1.42, (1.08 to 1.88)

0.012

1.28, (0.95 to 1.71)

0.103

 ≥0.5

190

16.8

1

 

1

 

Histologic grade

      

 Low-moderate grade

321

14.4

1

0.112

1

0.237

 High grade

11

6.9

1.92, (0.86 to 4.28)

 

1.50, (0.77 to 2.94)

 

Postoperative chemotherapy

      

 Fluorouracil

57

12.5

1.28, (0.85 to 1.93)

0.326

1.19, (0.80 to 1.76)

0.712

 Oxaliplatin base

140

16.8

1

 

1

 

 Irinotecan base

103

12.8

1.34, (0.85 to 1.93)

 

1.19, (0.85 to 1.65)

 

 No

32

13.6

1.00, (0.60 to 1.67)

 

1.15, (0.68 to 1.95)

 

Associated with bevacizumab

      

 Yes

46

17.0

1

0.496

—

—

 No

286

13.5

1.15, (0.77 to 1.72)

   

Associated with cetuximab

      

 Yes

6

7.4

1.80, (0.52 to 6.25)

0.352

—

—

 No

326

14.4

1

   

Chemotherapy cycles

      

 ≥6

232

15.4

1

0.233

—

—

 <6

100

9.7

1.21, (0.89 to 1.65)

   
  1. CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio; RFS, recurrence free survival.